Hinnah Campwala (left) is a Principal Scientist in the Cell Biology Development Group at Sartorius BioAnalytical Instruments (Michigan, USA). With a background in drug discovery and immune cell ...
Viral vectors dominate gene therapy, with lentivirus, adenovirus, and AAV being key players, each with unique advantages and limitations. Non-viral vectors, such as lipid nanoparticles and GalNAc, ...
In recent years, there has been an increase in the number of registered clinical trials evaluating recombinant adeno-associated virus (AAV)-based gene therapies, in part due to AAV’s ability to ...
In recent years, non-viral methods for cell engineering have emerged as promising alternatives to viral transduction. Amongst the virus-free technologies, electroporation is considered the gold ...
In this interview, News Med talks to Hinnah Campwala about the pivotal role of transfection in modern research and drug discovery. Transfection is a tool that sees widespread use across a diverse ...
No currently available treatment is able to generate new contractile tissue or significantly improve cardiac function after myocardial infarction (MI), a leading cause of morbidity and mortality ...
That’s gene editing. On paper, it is merely the rearrangement of letters. However, the road to editing genes in hopes of a therapeutic benefit is difficult to travel. Additionally, researchers want ...
Polymer-based gene delivery systems represent a promising class of non-viral vectors, offering significant advantages in safety, structural versatility, biodegradability, and the potential for ...
Researchers at the National University of Singapore (NUS) have developed a scalable, non-viral technology that efficiently delivers genetic material into human immune cells. The platform, called ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback